dGenThera is a next-generation targeted radiotherapeutics company advancing a differentiated pipeline of theranostic agents optimized for safety, scalability, and precision oncology. dGenThera’s proprietary chemistry enables exquisitely matched theranostic pairs—leveraging Astatine-211 (211At), Iodine-131 (131I), and Fluorine-18 (18F)—with engineered stable carbon-halogen bonds to drive accurate dosimetry, improve patient stratification, and reduce off-target toxicity.

dGenThera

Org chart

Teams

Offices